LATEST NEWS Press Releases & News Alerts AUG 20, 2025 Lucid Acts as Financial Advisor to Mural Oncology in its Acquisition by Xoma JUL 14, 2025 Lucid Provides Fairness Opinion in Connection with Sonnet’s Reverse Merger with HyperLiquid JUN 23, 2025 Lucid Provides Fairness Opinion in Connection with Carisma’s Reverse Merger with OrthoCellix JUN 16, 2025 Lucid Acts as Financial Advisor to GlycoMimetics in its Merger with Crescent Biopharma FEB 7, 2025 Lucid Acts as Sole Bookrunner for Nuvectis Pharma’s $15.5M Follow-on Offering DEC 31, 2024 Lucid Provides Fairness Opinion in Connection with Galera’s Acquisition of Nova Pharmaceuticals DEC 4, 2024 Lucid Acts as Lead Bookrunner for Eagle Point Credit Company $100 Million Notes Offering NOV 21, 2024 Lucid Acts as Lead Bookrunner for Ramaco Resources $50 Million Senior Notes Offering AUG 21, 2024 Lucid Established Healthcare Equity Research Group with Addition of Christopher Liu and Dev Prasad JUL 23, 2024 Lucid Establishes Specialty Finance Equity Research Group with the Hiring of Erik Zwick JUL 19, 2024 Lucid Establishes REIT Equity Research Group with the Hiring of Craig Kucera JUL 09, 2024 Lucid is named lead placement agent on Saratoga Investment Corporation’s $300 million ATM program JUN 26, 2024 Lucid Acts as Lead Left Bookrunner on $100M note offering of Oxford Lane Capital Corp JUN 18, 2024 Lucid acts as Lead Bookrunner on the $69 million IPO of Flagship Acquisition Corp. JUN 07, 2024 Lucid is named sole bookrunner of Rising Dragon Acquisition Corp.’s $50 million IPO MAY 10, 2024 Lucid is named sole bookrunner of YHN Acquisition Corp.’s $60 million IPO APR 03, 2024 Lucid is Named as Financial Advisor to ARCA Biopharma in a Reverse Merger Transaction with Oruka Therapeutics APR 03, 2024 Lucid is Named as Financial Advisor to Kintara Therapeutics in a Reverse Merger Transaction with TuHura Biosciences For press and news enquiries, please contact our team. PRESS ENQUIRIES
